Cellebrite DI (CLBT) Stock Price, News & Analysis

Company Overview

Cellebrite DI Ltd. is a digital intelligence company that develops technology for collecting, managing and analyzing digital evidence. Its solutions are designed to help law enforcement agencies, public safety organizations, government bodies and enterprises investigate activity involving mobile devices, computers, cloud services and other digital sources.

The company’s product portfolio includes tools for mobile-device extraction and digital forensics, investigative analytics, evidence management and collaboration. Its offerings include the UFED platform, Inseyets digital forensics solutions, Pathfinder investigative analytics and Guardian, a cloud-based platform intended to support the secure management and sharing of digital evidence and investigative workflows.

Founded in Israel, Cellebrite serves customers in numerous countries through a global sales and support network. The company became publicly traded on the Nasdaq under the symbol CLBT in 2021 following its business combination with special purpose acquisition company TWC Tech Holdings II Corp. Cellebrite’s customers primarily include government and law enforcement organizations, although it also provides solutions for corporate and other investigative users.

Key Stats

• Today's Range: $11.16 to $11.38
• 50-Day Range: $10.44 to $16.03
• 52-Week Range: $9.58 to $19.98
• Volume: 1.06 million shs
• Average Volume: 2.74 million shs
• Market Capitalization: $2.83 billion
• P/E Ratio: 40.09
• Dividend Yield: N/A
• Price Target: $16.70
• Consensus Rating: Moderate Buy

Cellebrite DI Stock Analysis - MarketRank™

Cellebrite DI scored higher than 86% of companies evaluated by MarketBeat, and ranked 99th out of 598 stocks in the technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cellebrite DI has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cellebrite DI has a consensus price target of $16.70, representing about 47.3% upside from its current price of $11.34.

Amount of Analyst Coverage

Cellebrite DI has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 37.84%

Earnings Growth

Earnings for Cellebrite DI are expected to grow by 37.84% in the coming year, from $0.37 to $0.51 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cellebrite DI is 51.55, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.82.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cellebrite DI is 51.55, which means that it is trading at a less expensive P/E ratio than the Technology sector average P/E ratio of about 80.62.

Price to Earnings Growth Ratio

Cellebrite DI has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Cellebrite DI has a P/B Ratio of 5.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.02% of the float of Cellebrite DI has been sold short.

Short Interest Ratio / Days to Cover

Cellebrite DI has a short interest ratio ("days to cover") of 3.49, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellebrite DI has recently increased by 14.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellebrite DI does not currently pay a dividend.

Dividend Growth

Cellebrite DI does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.11

News Sentiment

Cellebrite DI has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Technology companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Cellebrite DI this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for CLBT on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

MarketBeat Follows

5 people have added Cellebrite DI to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cellebrite DI insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,344,724.00 in company stock.

Percentage Held by Insiders

5.70% of the stock of Cellebrite DI is held by insiders.

Percentage Held by Institutions

45.88% of the stock of Cellebrite DI is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/11/2026
• Today: 10/08/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Technology
• Industry: Software
• Sub-Industry: Application Software
• Current Symbol: NASDAQ:CLBT
• CIK: 1854587
• Web: www.cellebrite.com
• Phone: 972-73-394-8000
• Fax: 972-3924-7104
• Employees: 1,285
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Cellebrite DI: $16.70
• High Price Target: $25.00
• Low Price Target: $12.50
• Potential Upside/Downside: +47.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.22
• Trailing P/E Ratio: 51.55
• Forward P/E Ratio: 30.65
• P/E Growth: 1.74
• Net Income: $78.33 million
• Net Margins: 11.43%
• Pretax Margin: 14.66%
• Return on Equity: 15.58%
• Return on Assets: 8.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.62
• Quick Ratio: 1.60

Sales & Book Value

• Annual Sales: $475.67 million
• Price / Sales: 5.95
• Cash Flow: $0.40 per share
• Price / Cash Flow: 28.14
• Book Value: $2.02 per share
• Price / Book: 5.61

Miscellaneous

• Outstanding Shares: 249,440,000
• Free Float: 235,222,000
• Market Cap: $2.83 billion
• Optionable: Optionable
• Beta: 1.14